Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017 Summary According to the recently published report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase'; Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis. The report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase' outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 2, 1, 8 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Breast Cancer, Prostate Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Hepatocellular Carcinoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Gastroesophageal (GE) Junction Carcinomas, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Leukemias, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing and Renal Cell Carcinoma. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects - The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview 9 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 15 Products under Development by Universities/Institutes 20 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment 22 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development 28 Argos Therapeutics Inc 28 Asterias Biotherapeutics Inc 28 e-Therapeutics Plc 29 F. Hoffmann-La Roche Ltd 29 Inovio Pharmaceuticals Inc 30 Invectys SA 30 Johnson & Johnson 31 Komipharm International Co Ltd 31 Mediolanum farmaceutici SpA 32 Telocyte LLC 32 TILT Biotherapeutics Ltd 33 Ultimovacs AS 33 Vaxon Biotech 33 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles 35 AGS-499 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ASTVAC-1 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ASTVAC-2 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Dendritic Cell Therapy + TILT-234 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ETS-2300 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Gene Therapy to Activate Telomerase for Alzheimer's Disease and Atherosclerosis - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 GX-301 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 imetelstat sodium - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 INO-1400 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 INO-5400 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 INO-5401 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 INVAC-1 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 KML-001 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 rocapuldencel-T - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Small Molecule to Inhibit Telomerase for Lung Cancer - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Small Molecules to Inhibit Telomerase for Oncology - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 telin - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 tertomotide - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 UCPVax - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 UV-1 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Vaccine to Target Telomerase for Cervical Cancer and Solid Tumor - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Vaccine to Target Telomerase Reverse Transcriptase for Solid Tumor - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Vbx-011 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Vbx-016 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Vbx-021 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Vbx-026 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Vx-001 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Vx-006 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products 92 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products 95 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones 97 Featured News & Press Releases 97 Sep 26, 2017: Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer 97 Sep 19, 2017: Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress 98 Sep 12, 2017: Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress 99 Sep 11, 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma 100 Aug 21, 2017: Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress 101 Aug 14, 2017: Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2 102 Jul 31, 2017: Geron Announces Updates to Imetelstat Clinical Development 102 Jun 01, 2017: Vaxon announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides 103 May 10, 2017: Argos Provides Update on its ADAPT Trial Following Meeting with FDA 104 Apr 26, 2017: Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia in 'Cancer' 105 Apr 18, 2017: Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial 106 Apr 10, 2017: Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen 107 Apr 05, 2017: Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting 109 Feb 22, 2017: Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review 109 Jan 19, 2017: Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University 110 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables
Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14 Number of Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19 Number of Products under Investigation by Universities/Institutes, H2 2017 20 Products under Investigation by Universities/Institutes, H2 2017 21 Number of Products by Stage and Mechanism of Actions, H2 2017 23 Number of Products by Stage and Route of Administration, H2 2017 25 Number of Products by Stage and Molecule Type, H2 2017 27 Pipeline by Argos Therapeutics Inc, H2 2017 28 Pipeline by Asterias Biotherapeutics Inc, H2 2017 29 Pipeline by e-Therapeutics Plc, H2 2017 29 Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 29 Pipeline by Inovio Pharmaceuticals Inc, H2 2017 30 Pipeline by Invectys SA, H2 2017 31 Pipeline by Johnson & Johnson, H2 2017 31 Pipeline by Komipharm International Co Ltd, H2 2017 32 Pipeline by Mediolanum farmaceutici SpA, H2 2017 32 Pipeline by Telocyte LLC, H2 2017 32 Pipeline by TILT Biotherapeutics Ltd, H2 2017 33 Pipeline by Ultimovacs AS, H2 2017 33 Pipeline by Vaxon Biotech, H2 2017 34 Dormant Products, H2 2017 92 Dormant Products, H2 2017 (Contd..1), H2 2017 93 Dormant Products, H2 2017 (Contd..2), H2 2017 94 Discontinued Products, H2 2017 95 Discontinued Products, H2 2017 (Contd..1), H2 2017 96
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
